Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longbitong is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Jichuan Pharmaceutical Group. It is primarily indicated for the treatment of urological conditions, specifically type 3 prostatitis (chronic prostatitis/chronic pelvic pain syndrome) and benign prostatic hyperplasia (BPH). The formulation is composed of several herbal ingredients, including *Astragalus membranaceus*, *Cistanche deserticola*, *Epimedium brevicornum*, and *Phellodendron amurense*. In TCM theory, it is designed to tonify the kidney, clear heat, and promote blood circulation to resolve stasis. Pharmacologically, Longbitong is believed to exert anti-inflammatory effects, reduce prostatic edema, and modulate the smooth muscle tone of the bladder neck and prostate, thereby improving lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, and pelvic pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longbitong.